This is a virtual panel discussion about whether biosimilars—cheaper copies of expensive biologic drugs—have finally gained enough market traction to meaningfully lower drug costs. The speakers explore what's working, what's broken in the system, and what comes next as more blockbuster drugs face biosimilar competition.

• The first wave of biosimilars has launched, with more major drugs facing lower-cost competition soon
• The FDA has been removing regulatory barriers to speed biosimilar approvals in an effort to reduce drug spending
• Policy shifts and structural problems in the healthcare system could derail the cost-savings momentum biosimilars have built

RFK Jr. challenges a Democratic senator’s claim that a 600% drug price drop is impossible by pointing out that if a price goes from $600 down to $100, that’s technically a 600% savings from the higher price. Trump chimes in with agreement.

• RFK Jr. claimed a drop from $600 to $100 equals a "600% savings," which is mathematically wrong (it's actually a 500/6 ≈ 83% decrease).
• Trump agreed with RFK Jr.'s flawed math in real time, saying "Right."
• The exchange was used by a reporter to illustrate how the administration frames drug pricing with misleading statistics.

The Department of Labor’s proposal would force pharmacy benefit managers to disclose drug pricing details to employers and open their books to audits. More than 500 comment letters show PBMs and insurers fighting the rule, while some employers and startups back it and drugmakers offer mixed support.

• DOL's proposed rule would force PBMs to disclose rebates, fees, and spread pricing to employers and submit to audits
• Over 500 comment letters split along predictable lines: PBMs/insurers oppose it as exposing confidential contracts, while Cost Plus Pharmacy and business groups support it as curbing hidden markups
• Drugmakers back reining in PBMs generally but want the disclosure rules narrowed to administrative fees, excluding drug-specific rebate data that competitors could exploit
• Rule could shift negotiating power from PBMs to employers, though employers would then face more complex data to manage in contract talks

Mark Cuban and Optum CEO Patrick Conway engaged in a heated discussion about drug prices and pharmacy benefit managers, highlighting their differing views on how to reform the healthcare system. Cuban argued for breaking up large insurance companies and criticized the lack of transparency in PBM contracts, while Conway emphasized the need to tackle high hospital and pharmaceutical costs. Both acknowledged the other's contributions but remained divided on the root causes of high drug prices and solutions.

• Cuban challenged Conway to name a specific Optum customer he could call to verify claims about PBM contract transparency
• Cuban advocates breaking up large insurance companies as a fix, blaming opaque PBM contracts for inflated drug prices
• Conway countered that high hospital and pharmaceutical costs, not just PBMs, are the core drivers of the problem
• Despite the confrontational exchange, both men acknowledged each other's contributions while disagreeing on root causes and solutions

TrumpRx, a new public-private program launched by the Trump administration in partnership with Pfizer, aims to offer direct-to-consumer drug sales at significantly reduced prices. While it seeks to provide discounts on medications, experts suggest it closely resembles existing DTC models like Cost Plus Drugs and may not substantially impact the majority of patients who rely on insurance for prescriptions.

• TrumpRx is a new public-private drug pricing program launched by the Trump administration with Pfizer offering direct-to-consumer sales at reduced prices.
• Experts say it closely resembles existing DTC models like Mark Cuban's Cost Plus Drugs rather than being a novel approach.
• Since most patients rely on insurance rather than paying cash for prescriptions, the program likely won't have a major impact on the majority of drug purchasers.